aminolevulinic acid has been researched along with Cancer of Prostate in 37 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5-aminolevulinic acid (5-ALA) is a constituent of mitochondrial electron carriers, heme and cytochrome c, which are crucial for aerobic energy metabolism and cell apoptosis." | 5.56 | Inhibitory Effect of Orally Administered 5-Aminolevulinic Acid on Prostate Carcinogenesis in the FVB-Transgenic Adenocarcinoma of a Mouse Prostate (FVB-TRAMP) Model. ( Anai, S; Fujimoto, K; Hori, S; Iemura, Y; Iida, K; Itami, Y; Miyake, M; Nakai, Y; Onishi, K; Onishi, S; Owari, T; Shimada, K; Tanaka, N; Tatsumi, Y, 2020) |
| "In the control group, prostate cancer was pathologically detected in 33 and 50 % of mice at 12 and 20 weeks, respectively, while 25% of 12-week old mice in the low-dose group were affected and none of the high-dose group mice developed prostate cancer." | 5.56 | Inhibitory Effect of Orally Administered 5-Aminolevulinic Acid on Prostate Carcinogenesis in the FVB-Transgenic Adenocarcinoma of a Mouse Prostate (FVB-TRAMP) Model. ( Anai, S; Fujimoto, K; Hori, S; Iemura, Y; Iida, K; Itami, Y; Miyake, M; Nakai, Y; Onishi, K; Onishi, S; Owari, T; Shimada, K; Tanaka, N; Tatsumi, Y, 2020) |
| "The sensitivity and specificity were 75." | 2.80 | Performance of 5-aminolevulinic-acid-based photodynamic diagnosis for radical prostatectomy. ( Fukuhara, H; Furihata, M; Inoue, K; Kurabayashi, A; Shuin, T, 2015) |
| "All 52 patients were diagnosed with prostate cancer by biopsy." | 2.80 | Performance of 5-aminolevulinic-acid-based photodynamic diagnosis for radical prostatectomy. ( Fukuhara, H; Furihata, M; Inoue, K; Kurabayashi, A; Shuin, T, 2015) |
| "Nineteen patients with localized prostate cancer were included in the study." | 2.72 | Photodynamic selectivity of 5-aminolevulinic acid to prostate cancer cells. ( Abdel-Gawad, O; El-Doray, AA; El-Mahdy, Ael-D; Hofstetter, A; Khoder, W; Sultan, SM, 2006) |
| "However, its therapeutic efficacy for prostate cancer is not yet fully understood." | 1.62 | Predictors of therapeutic efficacy of 5-aminolevulinic acid-based photodynamic therapy in human prostate cancer. ( Fukuhara, H; Inoue, K; Karashima, T; Kawada, C; Nakayama, T; Ogura, SI; Seki, H; Yamamoto, S, 2021) |
| "The human prostate cancer cell lines, PC-3, 22Rv1, DU145, and LNCap were used to investigate the effects of ALA-PDT on protoporphyrin IX (PpIX) intracellular accumulation, which was measured by flow cytometry." | 1.62 | Predictors of therapeutic efficacy of 5-aminolevulinic acid-based photodynamic therapy in human prostate cancer. ( Fukuhara, H; Inoue, K; Karashima, T; Kawada, C; Nakayama, T; Ogura, SI; Seki, H; Yamamoto, S, 2021) |
| "The current blood test for detecting prostate cancers measures prostate-specific antigen." | 1.56 | Plasma enabled devices for the selective capture and photodynamic identification of prostate cancer cells. ( Butler, L; Chan, KM; Gleadle, JM; Li, J; MacGregor, M; McNicholas, K; Ostrikov, K; Rouget, J; Shirazi, HS; Vasilev, K, 2020) |
| "Prostate cancer is the second most common cancer in men and the second leading cause of male cancer deaths." | 1.56 | Plasma enabled devices for the selective capture and photodynamic identification of prostate cancer cells. ( Butler, L; Chan, KM; Gleadle, JM; Li, J; MacGregor, M; McNicholas, K; Ostrikov, K; Rouget, J; Shirazi, HS; Vasilev, K, 2020) |
| "5-aminolevulinic acid (5-ALA) is a constituent of mitochondrial electron carriers, heme and cytochrome c, which are crucial for aerobic energy metabolism and cell apoptosis." | 1.56 | Inhibitory Effect of Orally Administered 5-Aminolevulinic Acid on Prostate Carcinogenesis in the FVB-Transgenic Adenocarcinoma of a Mouse Prostate (FVB-TRAMP) Model. ( Anai, S; Fujimoto, K; Hori, S; Iemura, Y; Iida, K; Itami, Y; Miyake, M; Nakai, Y; Onishi, K; Onishi, S; Owari, T; Shimada, K; Tanaka, N; Tatsumi, Y, 2020) |
| "In the control group, prostate cancer was pathologically detected in 33 and 50 % of mice at 12 and 20 weeks, respectively, while 25% of 12-week old mice in the low-dose group were affected and none of the high-dose group mice developed prostate cancer." | 1.56 | Inhibitory Effect of Orally Administered 5-Aminolevulinic Acid on Prostate Carcinogenesis in the FVB-Transgenic Adenocarcinoma of a Mouse Prostate (FVB-TRAMP) Model. ( Anai, S; Fujimoto, K; Hori, S; Iemura, Y; Iida, K; Itami, Y; Miyake, M; Nakai, Y; Onishi, K; Onishi, S; Owari, T; Shimada, K; Tanaka, N; Tatsumi, Y, 2020) |
| "Here we created uniformly sized PC-3 prostate cancer spheroids using a 3D culture plate (EZSPHERE)." | 1.43 | Dormant cancer cells accumulate high protoporphyrin IX levels and are sensitive to 5-aminolevulinic acid-based photodynamic therapy. ( Hagiya, Y; Inoue, K; Kobayashi, T; Matsumoto, K; Nakajima, M; Nakayama, T; Ogura, SI; Okajima, H; Otsuka, S; Shuin, T; Tanaka, T, 2016) |
| "Past attempts at detecting prostate cancer (PCa) cells in voided urine by traditional cytology have been impeded by undesirably low sensitivities but high specificities." | 1.40 | Photodynamic diagnosis of shed prostate cancer cells in voided urine treated with 5-aminolevulinic acid. ( Anai, S; Chihara, Y; Fujimoto, K; Hirao, Y; Hirayama, A; Kuwada, M; Miyake, M; Nakai, Y; Tanaka, N; Yoshida, K, 2014) |
| " Searching for new approaches, we tested a known inducer of cellular differentiation, methotrexate (MTX), in combination with ALA-PDT in LNCaP cells." | 1.33 | Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells. ( Anand, S; Chang, Y; Hasan, T; Mai, Z; Maytin, EV; Ortel, BJ; Sinha, AK, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (10.81) | 18.2507 |
| 2000's | 10 (27.03) | 29.6817 |
| 2010's | 15 (40.54) | 24.3611 |
| 2020's | 8 (21.62) | 2.80 |
| Authors | Studies |
|---|---|
| Abrahimi, P | 1 |
| McClure, T | 1 |
| Owari, T | 3 |
| Tanaka, N | 5 |
| Nakai, Y | 5 |
| Miyake, M | 5 |
| Anai, S | 5 |
| Kishi, S | 1 |
| Mori, S | 1 |
| Fujiwara-Tani, R | 1 |
| Hojo, Y | 1 |
| Mori, T | 1 |
| Kuwada, M | 2 |
| Fujii, T | 2 |
| Hasegawa, M | 1 |
| Fujimoto, K | 5 |
| Kuniyasu, H | 1 |
| Onbasli, K | 1 |
| Demirci, G | 1 |
| Isik, F | 1 |
| Durmusoglu, EG | 1 |
| Demir, HV | 1 |
| Acar, HY | 1 |
| Shirazi, HS | 1 |
| Chan, KM | 1 |
| Rouget, J | 1 |
| Ostrikov, K | 1 |
| McNicholas, K | 1 |
| Li, J | 1 |
| Butler, L | 1 |
| Gleadle, JM | 1 |
| Vasilev, K | 1 |
| MacGregor, M | 1 |
| Fukuhara, H | 7 |
| Yamamoto, S | 3 |
| Karashima, T | 3 |
| Inoue, K | 8 |
| Onishi, K | 1 |
| Tatsumi, Y | 2 |
| Hori, S | 3 |
| Onishi, S | 1 |
| Iemura, Y | 1 |
| Itami, Y | 2 |
| Iida, K | 2 |
| Shimada, K | 1 |
| Nakayama, T | 3 |
| Sano, T | 1 |
| Oshimo, Y | 1 |
| Kawada, C | 2 |
| Kasai, M | 1 |
| Ogura, SI | 3 |
| Seki, H | 1 |
| Morizawa, Y | 2 |
| Onisi, S | 1 |
| Ohnishi, S | 1 |
| Takahashi, H | 1 |
| Ohnishi, K | 1 |
| Gotoh, D | 1 |
| Inoue, T | 1 |
| Torimoto, K | 1 |
| Aoki, K | 1 |
| Bozzini, G | 1 |
| Colin, P | 1 |
| Betrouni, N | 1 |
| Maurage, CA | 1 |
| Leroy, X | 1 |
| Simonin, S | 1 |
| Martin-Schmitt, C | 1 |
| Villers, A | 1 |
| Mordon, S | 1 |
| Kurabayashi, A | 4 |
| Furihata, M | 4 |
| Fujita, H | 1 |
| Utsumi, K | 1 |
| Sasaki, J | 1 |
| Shuin, T | 5 |
| Ashida, S | 1 |
| Iiyama, T | 1 |
| Miyamura, M | 1 |
| Stein, RJ | 1 |
| Ko, O | 1 |
| Brandao, LF | 1 |
| Yamauchi, M | 1 |
| Honda, N | 1 |
| Hazama, H | 1 |
| Tachikawa, S | 1 |
| Nakamura, H | 1 |
| Kaneda, Y | 1 |
| Awazu, K | 1 |
| Chihara, Y | 1 |
| Hirayama, A | 1 |
| Yoshida, K | 1 |
| Hirao, Y | 1 |
| Otsuka, S | 1 |
| Kobayashi, T | 1 |
| Okajima, H | 1 |
| Matsumoto, K | 1 |
| Hagiya, Y | 1 |
| Nakajima, M | 1 |
| Tanaka, T | 1 |
| Adam, C | 3 |
| Salomon, G | 3 |
| Walther, S | 2 |
| Zaak, D | 4 |
| Khoder, W | 4 |
| Becker, A | 2 |
| Reich, O | 3 |
| Blana, A | 2 |
| Ganzer, R | 2 |
| Denzinger, S | 2 |
| Popken, G | 3 |
| Sroka, R | 3 |
| Knüchel-Clarke, R | 1 |
| Köllermann, J | 1 |
| Sauter, G | 1 |
| Hartmann, A | 2 |
| Bertz, S | 2 |
| Graefen, M | 1 |
| Huland, H | 1 |
| Wieland, W | 1 |
| Stief, CG | 3 |
| Egawa, S | 1 |
| Wieland, WF | 1 |
| Knuechel, R | 2 |
| Silva, FR | 1 |
| Bellini, MH | 1 |
| Nabeshima, CT | 1 |
| Schor, N | 1 |
| Vieira, ND | 1 |
| Courrol, LC | 1 |
| Satake, H | 1 |
| Tamura, K | 1 |
| Yamasaki, I | 1 |
| Tatsuo, I | 1 |
| Eichhorn, V | 1 |
| Maerz, A | 1 |
| Blanc, IF | 1 |
| Reuter, DA | 1 |
| Goetz, AE | 1 |
| Teper, E | 1 |
| Makhov, P | 1 |
| Golovine, K | 1 |
| Canter, DJ | 1 |
| Myers, CB | 1 |
| Kutikov, A | 1 |
| Sterious, SN | 1 |
| Uzzo, RG | 1 |
| Kolenko, VM | 1 |
| Hasan, T | 4 |
| Ortel, B | 1 |
| Sharlin, D | 1 |
| O'Donnell, D | 1 |
| Sinha, AK | 2 |
| Maytin, EV | 2 |
| Stocker, S | 1 |
| Bise, K | 1 |
| Lein, M | 1 |
| Höppner, M | 1 |
| Frimberger, D | 1 |
| Schneede, P | 1 |
| Kriegmair, M | 1 |
| Knüchel, R | 1 |
| Baumgartner, R | 2 |
| Hofstetter, A | 3 |
| Anand, S | 1 |
| Ortel, BJ | 1 |
| Chang, Y | 1 |
| Mai, Z | 1 |
| L'eplattenier, HF | 1 |
| Klem, B | 1 |
| Teske, E | 1 |
| van Sluijs, FJ | 1 |
| van Nimwegen, SA | 1 |
| Kirpensteijn, J | 1 |
| Stepp, H | 1 |
| Waidelich, R | 1 |
| Sultan, SM | 1 |
| El-Doray, AA | 1 |
| Abdel-Gawad, O | 1 |
| El-Mahdy, Ael-D | 1 |
| Tritschler, S | 1 |
| Karl, A | 1 |
| Tilki, D | 1 |
| Ahram, M | 1 |
| Cheong, WF | 1 |
| Ward, K | 1 |
| Kessel, D | 1 |
| Chang, SC | 1 |
| Buonaccorsi, GA | 1 |
| MacRobert, AJ | 1 |
| Bown, SG | 1 |
| Momma, T | 1 |
| Hamblin, MR | 1 |
| Chakrabarti, P | 1 |
| Orihuela, E | 1 |
| Egger, N | 1 |
| Neal, DE | 1 |
| Gangula, R | 1 |
| Adesokun, A | 1 |
| Motamedi, M | 1 |
3 reviews available for aminolevulinic acid and Cancer of Prostate
| Article | Year |
|---|---|
Emerging Intraoperative Imaging Technologies in Urologic Oncology.
Topics: Aminolevulinic Acid; Biomedical Technology; Carcinoma, Renal Cell; Fluorescence; Gallium Isotopes; G | 2022 |
Photodynamic diagnosis and therapy for urothelial carcinoma and prostate cancer: new imaging technology and therapy.
Topics: Aminolevulinic Acid; Carcinoma, Transitional Cell; Humans; Male; Photochemotherapy; Photosensitizing | 2021 |
[Fluorescence diagnosis and photodynamic therapy in urology].
Topics: Aminolevulinic Acid; Carcinoma in Situ; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II | 2007 |
6 trials available for aminolevulinic acid and Cancer of Prostate
| Article | Year |
|---|---|
Performance of 5-aminolevulinic-acid-based photodynamic diagnosis for radical prostatectomy.
Topics: Aged; Aminolevulinic Acid; Contrast Media; Humans; Image Enhancement; Laparoscopy; Male; Microscopy, | 2015 |
Photodynamic diagnosis using 5-aminolevulinic acid for the detection of positive surgical margins during radical prostatectomy in patients with carcinoma of the prostate: a multicentre, prospective, phase 2 trial of a diagnostic procedure.
Topics: Adenocarcinoma; Aged; Aminolevulinic Acid; Biopsy, Needle; Disease-Free Survival; Humans; Immunohist | 2009 |
Intraoperative photodynamic evaluation of surgical margins during endoscopic extraperitoneal radical prostatectomy with the use of 5-aminolevulinic acid.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aminolevulinic Acid; Biopsy; Dissection; Endoscopy; H | 2009 |
Photodynamic diagnosis of positive margin during radical prostatectomy: preliminary experience with 5-aminolevulinic acid.
Topics: Aged; Aminolevulinic Acid; Diagnostic Techniques, Urological; Feasibility Studies; Fluorescence; Hum | 2011 |
Hemodynamic effects of orally administered delta-ALA during radical prostatectomy.
Topics: Administration, Oral; Aged; Aminolevulinic Acid; Arterial Pressure; Case-Control Studies; Cohort Stu | 2013 |
Photodynamic selectivity of 5-aminolevulinic acid to prostate cancer cells.
Topics: Adenocarcinoma; Aged; Aminolevulinic Acid; Biological Availability; Combined Modality Therapy; Human | 2006 |
28 other studies available for aminolevulinic acid and Cancer of Prostate
| Article | Year |
|---|---|
5-Aminolevulinic acid overcomes hypoxia-induced radiation resistance by enhancing mitochondrial reactive oxygen species production in prostate cancer cells.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Humans; Hypoxia; Male; Mitochondria; Photochemotherapy; Photo | 2022 |
Aqueous colloidal nanoplatelets for imaging and improved ALA-based photodynamic therapy of prostate cancer cells.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Humans; Male; Nanoparticles; Photochemotherapy; Prostatic Neo | 2023 |
Plasma enabled devices for the selective capture and photodynamic identification of prostate cancer cells.
Topics: Aminolevulinic Acid; Cell Count; Cell Line, Tumor; Cell Nucleus; Fluorescence; Humans; Male; Microfl | 2020 |
Inhibitory Effect of Orally Administered 5-Aminolevulinic Acid on Prostate Carcinogenesis in the FVB-Transgenic Adenocarcinoma of a Mouse Prostate (FVB-TRAMP) Model.
Topics: Adenocarcinoma; Administration, Oral; Aminolevulinic Acid; Animals; Apoptosis; Carcinogenesis; Human | 2020 |
Enhanced lipid metabolism induces the sensitivity of dormant cancer cells to 5-aminolevulinic acid-based photodynamic therapy.
Topics: Aminolevulinic Acid; Coenzyme A Ligases; Humans; Lipid Metabolism; Male; PC-3 Cells; Photochemothera | 2021 |
Predictors of therapeutic efficacy of 5-aminolevulinic acid-based photodynamic therapy in human prostate cancer.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Humans; Male; Photochemotherapy; Photosensitizing Agents; Pro | 2021 |
Spectrophotometric photodynamic diagnosis of prostate cancer cells excreted in voided urine using 5-aminolevulinic acid.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Area Under Curve; Biomarkers, Tumor; Biopsy; Ce | 2018 |
Dual benefit of supplementary oral 5-aminolevulinic acid to pelvic radiotherapy in a syngenic prostate cancer model.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Male; Mice | 2019 |
Efficiency of 5-ALA mediated photodynamic therapy on hypoxic prostate cancer: a preclinical study on the Dunning R3327-AT2 rat tumor model.
Topics: Aminolevulinic Acid; Animals; Cell Hypoxia; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug The | 2013 |
The inhibition of ferrochelatase enhances 5-aminolevulinic acid-based photodynamic action for prostate cancer.
Topics: Aminolevulinic Acid; Animals; Apoptosis; Cell Line, Tumor; Chloroquine; Deferoxamine; Drug Synergism | 2013 |
Application of 5-aminolevulinic acid-mediated photodynamic diagnosis to robot-assisted laparoscopic radical prostatectomy.
Topics: Aged; Aminolevulinic Acid; Biopsy; Diagnosis, Computer-Assisted; Fluorescence; Humans; Laparoscopy; | 2013 |
Editorial comment.
Topics: Aminolevulinic Acid; Humans; Laparoscopy; Male; Photosensitizing Agents; Prostate; Prostatectomy; Pr | 2013 |
A novel photodynamic therapy for drug-resistant prostate cancer cells using porphyrus envelope as a novel photosensitizer.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Drug Delivery Systems; Humans; Male; Photochemotherapy; Photo | 2014 |
Photodynamic diagnosis of shed prostate cancer cells in voided urine treated with 5-aminolevulinic acid.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Biomarkers, Tumor; Feasibility Studies; Humans; Male; | 2014 |
Dormant cancer cells accumulate high protoporphyrin IX levels and are sensitive to 5-aminolevulinic acid-based photodynamic therapy.
Topics: Aminolevulinic Acid; Biomarkers, Tumor; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Hu | 2016 |
Nondestructive testing in urologic oncology.
Topics: Aminolevulinic Acid; Forecasting; Humans; Male; Medical Oncology; Microscopy, Fluorescence; Prostate | 2009 |
Enhancement of blood porphyrin emission intensity with aminolevulinic acid administration: a new concept for photodynamic diagnosis of early prostate cancer.
Topics: Administration, Oral; Aminolevulinic Acid; Animals; Cell Line, Tumor; Drug Synergism; Drug Therapy, | 2011 |
The effect of 5-aminolevulinic acid and its derivatives on protoporphyrin IX accumulation and apoptotic cell death in castrate-resistant prostate cancer cells.
Topics: Aminolevulinic Acid; Apoptosis; Cell Line, Tumor; Chelating Agents; Ethylenediamines; Humans; Male; | 2012 |
Using cellular mechanisms to develop effective combinations of photodynamic therapy and targeted therapies.
Topics: Aminolevulinic Acid; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; | 2012 |
Differentiation enhances aminolevulinic acid-dependent photodynamic treatment of LNCaP prostate cancer cells.
Topics: Aminolevulinic Acid; Cell Differentiation; Flow Cytometry; Humans; Male; Metribolone; Photochemother | 2002 |
Photodynamic therapy of prostate cancer by means of 5-aminolevulinic acid-induced protoporphyrin IX - in vivo experiments on the dunning rat tumor model.
Topics: Aminolevulinic Acid; Animals; Disease Models, Animal; Male; Photochemotherapy; Prostatic Neoplasms; | 2004 |
Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells.
Topics: Aminolevulinic Acid; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Sur | 2006 |
Preliminary results of intraoperative photodynamic therapy with 5-aminolevulinic acid in dogs with prostate carcinoma.
Topics: Aminolevulinic Acid; Animals; Combined Modality Therapy; Dog Diseases; Dogs; Intraoperative Care; Ma | 2008 |
Photodynamic diagnosis of prostate cancer using 5-aminolevulinic acid--first clinical experiences.
Topics: Aminolevulinic Acid; Feasibility Studies; Humans; Male; Microscopy, Fluorescence; Neoplasm Staging; | 2008 |
Photoproduct formation during irradiation of tissues containing protoporphyrin.
Topics: Aminolevulinic Acid; Animals; Leukemia L1210; Light; Male; Mice; Prostatic Neoplasms; Protoporphyrin | 1994 |
Interstitial photodynamic therapy in the canine prostate with disulfonated aluminum phthalocyanine and 5-aminolevulinic acid-induced protoporphyrin IX.
Topics: Aminolevulinic Acid; Animals; Atrophy; Collagen; Dogs; Indoles; Lasers; Light; Male; Organometallic | 1997 |
Hormonal modulation of the accumulation of 5-aminolevulinic acid-induced protoporphyrin and phototoxicity in prostate cancer cells.
Topics: Aminolevulinic Acid; Animals; Blood; Cattle; Cell Division; Cell Survival; Culture Media; Dihydrotes | 1997 |
Delta-aminolevulinic acid-mediated photosensitization of prostate cell lines: implication for photodynamic therapy of prostate cancer.
Topics: Aminolevulinic Acid; Cell Survival; Humans; Male; Microscopy, Electron; Mitochondria; Photochemother | 1998 |